We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
Key Takeaways
Moderna's Q3 earnings crushed expectations, driven by stronger vaccine sales and improved profitability.
MRNA has surged over 700% YTD, reflecting optimism for its cancer vaccine pipeline and improving outlook.
Moderna's elevated valuation raises concerns, making a sharp pullback a potentially better buying opportunity.
Moderna (MRNA - Free Report) ) stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high of $267 a share after the biotechnology giant delivered much stronger-than-expected Q3 results.
The rally comes as investors increasingly gravitate toward healthcare stocks for defensive safety amid the broader technology selloff, with industry giants AbbVie (ABBV - Free Report) ) and Eli Lilly (LLY - Free Report) ) recently reaching new highs as well.
However, with Moderna stock extending an extraordinary year-to-date rally of nearly 800%, investors may be wondering whether to chase the momentum or await a more attractive entry point.
Much of MRNA's remarkable surge has been fueled by positive Phase 3 melanoma trial results for its personalized cancer vaccine being developed with Merck (MRK - Free Report) ), alongside improving financial performance and optimism surrounding its expanding vaccine portfolio.
Image Source: Zacks Investment Research
Moderna's Q3 Earnings Crush Expectations
Moderna reported Q3 earnings of $0.38 per share, crushing expectations that called for a loss of $1.10 per share by 134% and reversing a loss of $0.51 in the year-ago quarter.
Quarterly revenue jumped 29% year over year to $1.31 billion, comfortably surpassing estimates of $889 million. Growth was primarily driven by stronger international COVID-19 vaccine sales, supported by long-term government supply agreements.
Encouragingly, Moderna generated $162 million in net income compared with a $200 million loss a year earlier, aided by a 27% reduction in research and development (R&D) expenses.
Image Source: Zacks Investment Research
Moderna Provides Upbeat Guidance
Adding to the optimism, Moderna raised its full-year 2026 revenue growth outlook to 15%-25%, up from its previous forecast of up to 10% growth and ahead of Wall Street’s expectations of $2.1 billion in annual sales or 8% growth (Current Year Below).
Management also lowered its R&D spending outlook to approximately $2.7 billion from $2.9 billion.
Image Source: Zacks Investment Research
Moderna's Valuation Raises Concerns After Massive Rally
Despite its impressive operating improvements, Moderna's valuation presents significant risks following its extraordinary YTD rally.
To that point, MRNA commands a market capitalization exceeding $100 billion and trades near 40X forward sales, an exceptionally rich premium for a biotechnology company still working toward sustainable profitability.
With Moderna remaining unprofitable over the last 12 months, traditional forward P/E comparisons are less useful, making its elevated price-to-sales multiple particularly concerning.
While the company's expanding pipeline offers substantial long-term potential, much of that optimism may already be reflected in its stock price.
Image Source: Zacks Investment Research
Bottom Line: Buy, Hold, or Sell MRNA?
Moderna currently lands a Zacks Rank #3 (Hold), suggesting investors may want to avoid chasing the post-earnings spike despite the company's impressive Q3 results and improved outlook.
With MRNA extending its massive year-to-date rally, better buying opportunities could certainly be ahead. However, Moderna stock could become an ideal buy-the-dip target on a sharp pullback, particularly if its improving fundamentals and promising pipeline remain intact.
View the Zacks #1 Rank List
Image: Bigstock
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
Key Takeaways
Moderna (MRNA - Free Report) ) stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high of $267 a share after the biotechnology giant delivered much stronger-than-expected Q3 results.
The rally comes as investors increasingly gravitate toward healthcare stocks for defensive safety amid the broader technology selloff, with industry giants AbbVie (ABBV - Free Report) ) and Eli Lilly (LLY - Free Report) ) recently reaching new highs as well.
However, with Moderna stock extending an extraordinary year-to-date rally of nearly 800%, investors may be wondering whether to chase the momentum or await a more attractive entry point.
Much of MRNA's remarkable surge has been fueled by positive Phase 3 melanoma trial results for its personalized cancer vaccine being developed with Merck (MRK - Free Report) ), alongside improving financial performance and optimism surrounding its expanding vaccine portfolio.
Image Source: Zacks Investment Research
Moderna's Q3 Earnings Crush Expectations
Moderna reported Q3 earnings of $0.38 per share, crushing expectations that called for a loss of $1.10 per share by 134% and reversing a loss of $0.51 in the year-ago quarter.
Quarterly revenue jumped 29% year over year to $1.31 billion, comfortably surpassing estimates of $889 million. Growth was primarily driven by stronger international COVID-19 vaccine sales, supported by long-term government supply agreements.
Encouragingly, Moderna generated $162 million in net income compared with a $200 million loss a year earlier, aided by a 27% reduction in research and development (R&D) expenses.
Image Source: Zacks Investment Research
Moderna Provides Upbeat Guidance
Adding to the optimism, Moderna raised its full-year 2026 revenue growth outlook to 15%-25%, up from its previous forecast of up to 10% growth and ahead of Wall Street’s expectations of $2.1 billion in annual sales or 8% growth (Current Year Below).
Management also lowered its R&D spending outlook to approximately $2.7 billion from $2.9 billion.
Image Source: Zacks Investment Research
Moderna's Valuation Raises Concerns After Massive Rally
Despite its impressive operating improvements, Moderna's valuation presents significant risks following its extraordinary YTD rally.
To that point, MRNA commands a market capitalization exceeding $100 billion and trades near 40X forward sales, an exceptionally rich premium for a biotechnology company still working toward sustainable profitability.
With Moderna remaining unprofitable over the last 12 months, traditional forward P/E comparisons are less useful, making its elevated price-to-sales multiple particularly concerning.
While the company's expanding pipeline offers substantial long-term potential, much of that optimism may already be reflected in its stock price.
Image Source: Zacks Investment Research
Bottom Line: Buy, Hold, or Sell MRNA?
Moderna currently lands a Zacks Rank #3 (Hold), suggesting investors may want to avoid chasing the post-earnings spike despite the company's impressive Q3 results and improved outlook.
With MRNA extending its massive year-to-date rally, better buying opportunities could certainly be ahead. However, Moderna stock could become an ideal buy-the-dip target on a sharp pullback, particularly if its improving fundamentals and promising pipeline remain intact.